Mihael Polymeropoulos, Vanda Pharmaceuticals CEO

Van­da's gas­tric drug flops in late-stage test, crash­ing the biotech's stock

You may re­mem­ber Van­da Phar­ma­ceu­ti­cals from its brief feud with the FDA over a par­tial clin­i­cal hold on gas­tric drug tradip­i­tant — a fight it would lose in court a cou­ple years ago. Now, that same drug is in hot wa­ter af­ter fail­ing a piv­otal test.

Tradip­i­tant, an in-li­censed drug from Eli Lil­ly be­ing test­ed in gas­tro­pare­sis, flopped a Phase III study look­ing to re­duce nau­sea symp­toms against place­bo, the biotech said Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.